-
摘要: 前列腺癌(prostate cancer，PCa)是男性泌尿生殖系统中最为常见的恶性肿瘤之一，前列腺穿刺是目前诊断PCa的金标准。非典型小腺泡增生(atypical small acinar proliferation，ASAP)在穿刺病理报告中并不少见，表现为疑似癌却又不能确定为癌的一种病理现象。但目前ASAP对发展为有临床意义的PCa风险作用尚不清楚，对于立即或推迟再次活检缺少共识。本文就ASAP病理学特征、对PCa的预测因素、预测概率和再活检作综述，以指导泌尿外科医生作出最佳决策。Abstract: Prostate cancer(PCa) is one of the most common malignancies of the male urogenital system. Prostate biopsy is the gold standard for the diagnosis of PCa. Atypical small acinar proliferation(ASAP) is not uncommon and considered as suspicious atypical foci, but it is not diagnostic for malignancy. However, the role of ASAP on the risk of developing clinically significant PCa is currently unclear and there is no consensus about the best strategy: immediate versus deferred re-biopsy. In this review, we will summarize the characteristics of ASAP pathology, the predictive factors for PCa and re-biopsy strategy to guide urological surgeons in making optimal decisions.
-
Key words:
- atypical small acinar proliferation /
- prostate cancer /
- needle biopsy /
- re-biopsy
-
-
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2] 陈志华, 蒋国松, 阮海龙, 等. 机器人辅助腹腔镜前列腺癌根治术治疗高危局部进展期前列腺癌临床疗效分析[J]. 临床泌尿外科杂志, 2022, 37(2): 123-126. doi: 10.13201/j.issn.1001-1420.2022.02.010 https://lcmw.whuhzzs.com/article/doi/10.13201/j.issn.1001-1420.2022.02.010
[3] Dorin RP, Wiener S, Harris CD, et al. Prostate atypia: does repeat biopsy detect clinically significant prostate cancer?[J]. Prostate, 2015, 75(7): 673-678. doi: 10.1002/pros.22950
[4] Ericson KJ, Wenger HC, Rosen AM, et al. Prostate cancer detection following diagnosis of atypical small acinar proliferation[J]. Can J Urol, 2017, 24(2): 8714-8720.
[5] Oderda M, Rosazza M, Agnello M, et al. Natural history of widespread high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: should we rebiopsy them all?[J]. Scand J Urol, 2021, 55(2): 129-134. doi: 10.1080/21681805.2020.1866659
[6] Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer[J]. J Clin Oncol, 2015, 33(30): 3379-3385. doi: 10.1200/JCO.2015.62.5764
[7] Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines[J]. J Natl Compr Canc Netw, 2014, 12(9): 1211-1219;quiz 1219. doi: 10.6004/jnccn.2014.0120
[8] Amin M, Boccon-Gibod L, Egevad L, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens[J]. Scand J Urol Nephrol Suppl, 2005(216): 20-33.
[9] Montironi R, Scattoni V, Mazzucchelli R, et al. Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies(also referred to as atypical small acinar proliferation suspicious for but not diagnostic of malignancy)[J]. Eur Urol, 2006, 50(4): 666-674. doi: 10.1016/j.eururo.2006.07.048
[10] Iczkowski KA. Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains[J]. Arch Pathol Lab Med, 2006, 130(6): 835-843. doi: 10.5858/2006-130-835-CPBICF
[11] Bostwick DG, Meiers I. Atypical small acinar proliferation in the prostate: clinical significance in 2006[J]. Arch Pathol Lab Med, 2006, 130(7): 952-957. doi: 10.5858/2006-130-952-ASAPIT
[12] 石怀银, 韦立新, 周振鸿, 等. 前列腺不典型小腺泡增生的病理形态及临床意义[J]. 中华病理学杂志, 2006, 35(11): 660-663. doi: 10.3760/j.issn:0529-5807.2006.11.007
[13] Yang C, Humphrey PA. False-negative histopathologic diagnosis of prostatic adenocarcinoma[J]. Arch Pathol Lab Med, 2020, 144(3): 326-334. doi: 10.5858/arpa.2019-0456-RA
[14] 马小兵, 畅继武. 前列腺不典型小腺泡增生[J]. 临床与实验病理学杂志, 2007, 23(6): 717-720. doi: 10.3969/j.issn.1001-7399.2007.06.019
[15] Adamczyk P, Wolski Z, Butkiewicz R, et al. Significance of atypical small acinar proliferation and extensive high-grade prostatic intraepithelial neoplasm in clinical practice[J]. Cent European J Urol, 2014, 67(2): 136-141.
[16] 陈玉玲, 樊翔, 王国庆, 等. 前列腺导管内癌的病理特征及临床意义[J]. 诊断病理学杂志, 2019, 26(9): 595-599. doi: 10.3969/j.issn.1007-8096.2019.09.011
[17] Kim H, Kim JK, Choe G, et al. Clinical strategy of repeat biopsy in patients with atypical small acinar proliferation(ASAP)[J]. Sci Rep, 2021, 11(1): 23143. doi: 10.1038/s41598-021-02172-8
[18] Ynalvez LA, Kosarek CD, Kerr PS, et al. Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm[J]. Int Urol Nephrol, 2018, 50(1): 1-6. doi: 10.1007/s11255-017-1714-8
[19] Scattoni V, Roscigno M, Freschi M, et al. Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies[J]. Urology, 2005, 66(5): 1043-1047. doi: 10.1016/j.urology.2005.05.006
[20] Ryu JH, Kim YB, Lee JK, et al. Predictive factors of prostate cancer at repeat biopsy in patients with an initial diagnosis of atypical small acinar proliferation of the prostate[J]. Korean J Urol, 2010, 51(11): 752-756. doi: 10.4111/kju.2010.51.11.752
[21] Totaro A, Di Gianfrancesco L, Pinto F, et al. Rate of clinically significant prostate cancer on repeat saturation biopsy after a diagnosis of atypical small acinar proliferation[J]. Urologia, 2021, 88(3): 194-199. doi: 10.1177/0391560321993595
[22] Warlick C, Feia K, Tomasini J, et al. Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation[J]. Prostate Cancer Prostatic Dis, 2015, 18(3): 255-259. doi: 10.1038/pcan.2015.14
[23] Mearini L, Costantini E, Bellezza G, et al. Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation?[J]. Urol Int, 2008, 81(1): 29-35. doi: 10.1159/000137637
[24] O'Connor E, Dowling C, Casey M, et al. Implications of a diagnosis of atypical small acinar proliferation(ASAP)and high-grade prostatic intraepithelial neoplasia(HGPIN)on prostate biopsy: a 5-year follow-up study[J]. Ir J Med Sci, 2022, 191(5): 2035-2040. doi: 10.1007/s11845-021-02854-2
[25] Leone L, Lacetera V, Montironi R, et al. Biopsy follow-up in patients with isolated atypical small acinar proliferation(ASAP)in prostate biopsy[J]. Arch Ital Urol Androl, 2014, 86(4): 332-335. doi: 10.4081/aiua.2014.4.332
[26] Leone A, Rotker K, Butler C, et al. Atypical small acinar proliferation: repeat biopsy and detection of high grade prostate cancer[J]. Prostate Cancer, 2015, 2015: 810159.
[27] Leone A, Gershman B, Rotker K, et al. Atypical small acinar proliferation(ASAP): is a repeat biopsy necessary ASAP?A multi-institutional review[J]. Prostate Cancer Prostatic Dis, 2016, 19(1): 68-71. doi: 10.1038/pcan.2015.52
[28] Koca O, Calışkan S, Oztürk M, et al. Significance of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia in prostate biopsy[J]. Korean J Urol, 2011, 52(11): 736-740. doi: 10.4111/kju.2011.52.11.736
[29] Srirangam V, Rai BP, Abroaf A, et al. Atypical small acinar proliferation and high grade prostatic intraepithelial neoplasia: should we be concerned?an observational cohort study with a minimum follow-up of 3 years[J]. Curr Urol, 2017, 10(4): 199-205. doi: 10.1159/000447181
[30] Cool DW, Romagnoli C, Izawa JI, et al. Comparison of prostate MRI-3D transrectal ultrasound fusion biopsy for first-time and repeat biopsy patients with previous atypical small acinar proliferation[J]. Can Urol Assoc J, 2016, 10(9-10): 342-348.
[31] Merrick GS, Galbreath RW, Bennett A, et al. Incidence, grade and distribution of prostate cancer following transperineal template-guided mapping biopsy in patients with atypical small acinar proliferation[J]. World J Urol, 2017, 35(7): 1009-1013. doi: 10.1007/s00345-016-1976-2
[32] Wiener S, Haddock P, Cusano J, et al. Incidence of clinically significant prostate cancer after a diagnosis of atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, or benign tissue[J]. Urology, 2017, 110: 161-165. doi: 10.1016/j.urology.2017.08.040
[33] El-Hakim A, Moussa S. CUA guidelines on prostate biopsy methodology[J]. Can Urol Assoc J, 2010, 4(2): 89-94. doi: 10.5489/cuaj.10021
[34] Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013[J]. Eur Urol, 2014, 65(1): 124-137. doi: 10.1016/j.eururo.2013.09.046
[35] Raskolnikov D, Rais-Bahrami S, George AK, et al. The role of image guided biopsy targeting in patients with atypical small acinar proliferation[J]. J Urol, 2015, 193(2): 473-478. doi: 10.1016/j.juro.2014.08.083
[36] Manning TG, Cheung E, Perera M, et al. Atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia in the era of multiparametric magnetic resonance imaging: a contemporary review[J]. Urology, 2017, 107: 5-10. doi: 10.1016/j.urology.2017.04.021
[37] Tsivian M, Gupta RT, Tsivian E, et al. Assessing clinically significant prostate cancer: diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology[J]. Int J Urol, 2017, 24(2): 137-143. doi: 10.1111/iju.13251
[38] Birs A, Joyce PH, Pavlovic ZJ, et al. Diagnosis and monitoring of prostatic lesions: a comparison of three modalities: multiparametric MRI, fusion MRI/transrectal ultrasound(TRUS), and traditional TRUS[J]. Cureus, 2016, 8(7): e702.
[39] Kim KH, Kim YB, Lee JK, et al. Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer[J]. Korean J Urol, 2010, 51(6): 398-402. doi: 10.4111/kju.2010.51.6.398
-
计量
- 文章访问数: 1177
- PDF下载数: 517
- 施引文献: 0
下载: